Biomedical Engineering Reference
In-Depth Information
patients: comparison between continuous ambulatory peritoneal dialysis and
hemodialysis populations. Am. J. Kidney Dis. 11, 473±476 (1988).
73. Jadoul, M., Garbar, C., & Vanholder, R. High prevalence of histological beta2-
microglobulin amyloidosis in CAPD patients. Nephrol., Dial., Transplant. 12, A175
(1997).
74. Jadoul, M. Dialysis-related amyloidosis: importance of biocompatibility and age.
Nephrol. Dial. Transplant. 13 Suppl 7, 61±64 (1998).
75. van Ypersele, D.S., Jadoul, M., Malghem, J., Maldague, B., & Jamart, J. Effect of
dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The
Working Party on Dialysis Amyloidosis. Kidney Int. 39, 1012±1019 (1991).
76. Niwa, T. Dialysis-related amyloidosis: pathogenesis
focusing on AGE
modification. Semin. Dial. 14, 123±126 (2001).
77. Wada, T., Miyata, T., Sakai, H., & Kurokawa, K. Beta2-microglobulin and renal
bone disease. Perit. Dial. Int. 19 Suppl 2, S413±S416 (1999).
78. Haberal, M. et al. The impact of cyclosporine on the development of
immunosuppressive therapy. Transplant. Proc. 36, 143S±147S (2004).
79. Duncan, M.D. & Wilkes, D.S. Transplant-related Immunosuppression: a review of
immunosuppression and pulmonary infections. Proc. Am. Thorac. Soc. 2, 449±455
(2005).
80. Patel, R. & Paya, C.V. Infections in solid-organ transplant recipients. Clin.
Microbiol. Rev. 10, 86±124 (1997).
81. Snydman, D.R. Epidemiology of infections after solid-organ transplantation. Clin.
Infect. Dis. 33 Suppl 1, S5±S8 (2001).
82. Chang, T.M. Semipermeable aqueous microcapsules (`artificial cells'): with
emphasis on experiments in an extracorporeal shunt system. Trans. Am. Soc. Artif.
Intern. Organs 12, 13±19 (1966).
83. Chang, T.M. Therapeutic applications of polymeric artificial cells. Nat. Rev. Drug
Discov. 4, 221±235 (2005).
84. Chang, T.M. The role of artificial cells in cell and organ transplantation in
regenerative medicine. Panminerva Med. 47, 1±9 (2005).
85. Chang, T.M.S & Prakash, S. Therapeutic uses of microencapsulated genetically
engineered cells. Mol. Med. Today, 4(5), 221±227 (1998).
86. Chang, T.M.S. Artificial cells for replacement of metabolic organ functions. Artif.
Cells Blood Substit. Immobiliz. Biotechnol. 31, 151±161 (2003).
87. Di Campli, C. et al. Use of hemodialysis with albumin (MARS) for liver antibiotic
toxicity in a patient with systemic tubercolosis. Hepatology 36, 680A (2002).
88. Di Campli, C. et al. Advances in extracorporeal detoxification by MARS dialysis in
patients with liver failure. Current Med. Chem. 10, 341±348 (2003).
89. Gerlach, J.C. et al. Use of primary human liver cells originating from discarded
grafts in a bioreactor for liver support therapy and the prospects of culturing adult
liver stem cells in bioreactors: a morphologic study. Transplantation 76, 781±786
(2003).
90. Gottschalk, C.W. & Fellner, S.K. History of the science of dialysis. Am. J. Nephrol.
17, 289±298 (1997).
91. Cimino, J.E. & Brescia, M.J. Simple venipuncture for hemodialysis. Nord. Hyg.
Tidskr. 267, 608±609 (1962).
92. Chang, T.M., MacIntosh, F.C., & Mason, S.G. Semipermeable aqueous
microcapsules. I. Preparation and properties. Can. J. Physiol Pharmacol. 44,
115±128 (1966).
93. Chang, T.M. & Malave, N. The development and first clinical use of
Search WWH ::
Custom Search